First published in the Government *Gazette*, Electronic Edition, on 29 November 2019 at 5 pm.

No. S 792

MISUSE OF DRUGS ACT
(CHAPTER 185)

MISUSE OF DRUGS ACT
(AMENDMENT OF FIRST, FOURTH AND FIFTH SCHEDULES) ORDER 2019

In exercise of the powers conferred by sections 58A and 59 of the Misuse of Drugs Act, the Minister for Home Affairs makes the following Order:

Citation and commencement

1. This Order is the Misuse of Drugs Act (Amendment of First, Fourth and Fifth Schedules) Order 2019 and comes into operation on 1 December 2019.

Amendment of Part I of First Schedule

2. Part I of the First Schedule to the Misuse of Drugs Act is amended —

(*a*) by inserting, immediately after item (36) of paragraph 1, the following item:

"(36A) N,N-Diethyl-3-hydroxy-7-methyl-2-oxo-4,6,6a,7,8,9-hexahydroindolo-[4,3-*fg*]quinoline-9-carboxamide (also known as 2-Oxo-3-hydroxy-LSD) and its acyclic secondary and tertiary amide structural isomers";

(*b*) by deleting items (45), (46) and (47) of paragraph 1 and substituting the following items:

"(45) 2,5-Dimethoxy-α-methylphenethylamine (also known as 2,5-Dimethoxyamphetamine or DMA) and its dimethoxy positional isomers in the phenyl ring

(46) N,α-Dimethyl-3,4-(methylenedioxy)phenethylamine (also known as 3,4-Methylenedioxymethamphetamine or MDMA)

(47) 3-(1,2-Dimethylhepty1)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran (also known as DMHP)";

(*c*) by deleting item (55) of paragraph 1 and substituting the following item:

"(55) 4-Ethyl-2,5-dimethoxy-α-methylphenethylamine (also known as DOET)";

(*d*) by deleting item (85) of paragraph 1 and substituting the following item:

"(85) 3-Methoxy-α-methyl-4,5-(methylenedioxy) phenethylamine (also known as 5-methoxy-MDA or MMDA)";

(*e*) by deleting item (88) of paragraph 1 and substituting the following item:

"(88) N-[α-Methyl-3,4-(methylenedioxy)phenethyl] hydroxylamine (also known as N-Hydroxy MDA)";

(*f*) by deleting item (140) of paragraph 1 and substituting the following item:

"(140) 3,4,5-Trimethoxy-α-methylphenethylamine (also known as TMA)";

(*g*) by inserting, immediately after item (8AA) of paragraph 16, the following item:

"(8AAB) 1-(4-Chlorophenyl)-2-(dimethylamino)propan-1-one (also known as 4-Chloro-N,N-dimethylcathinone)";

(*h*) by deleting item (13) of paragraph 16 and substituting the following item:

"(13) 2-(Ethylamino)-1-phenylpentan-1-one (also known as α-Ethylaminopentiophenone or N-Ethylpentedrone)";

(*i*) by deleting items (1), (1AAA), (1AA) and (1A) of paragraph 18 and substituting the following items:

"(1) 1-Acetyl-N,N-diethyllysergamide (also known as N-Acetyl-LSD or ALD-52) and its acyclic secondary and tertiary amide structural isomers

(1A) N-(1-Adamantyl)-5-bromopentyl-1H-indazole-3-carboxamide (also known as 5-Bromo-APINACA or 5-Bromo-AKB48) and its bromo positional isomers in the pentyl group

(1AA) 5-{3-[(1-Adamantyl)carbamoyl]-1H-indazole-1-yl} pentanoic acid

(1AB) N-(1-Adamantyl)-5-chloropentyl-1H-indazole-3-carboxamide (also known as 5-Chloro-APINACA or 5-Chloro-AKB48) and its chloro positional isomers in the pentyl group

(1AC) N-(Adamant-1-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as Adamantyl CHMINACA or SGT-37)

(1AD) N-(1-Adamantyl)-5-hydroxypentyl-1H-indazole-3-carboxamide and its hydroxy positional isomers in the pentyl group

(1AE) N-(1-Adamantyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as FUB-APINACA or FUB-AKB48) and its fluoro positional isomers in the phenyl ring

(1AF) N-(1-Adamantyl)-5-fluoropentyl-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48) and its fluoro positional isomers in the pentyl group

(1AG) N-(1-Adamantyl)-5-fluoropentyl-1H-indole-3-carboxamide (also known as 5-Fluoro-APICA or STS-135) and its fluoro positional isomers in the pentyl group";

(*j*) by inserting, immediately after item (2A) of paragraph 18, the following items:

"(2AA) 5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl) carbamoyl]-1H-indazole-1-yl}pentanoic acid and its N-(1-amino-1-oxohexan-2-yl) isomers

(2AB) 5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl) carbamoyl]-1H-indole-1-yl}pentanoic acid and its N-(1-amino-1-oxohexan-2-yl) isomers";

(*k*) by inserting, immediately after item (2C) of paragraph 18, the following item:

"(2CA) N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as 5-Fluoro-ADBICA) and its N-(1-amino-1-oxohexan-2-yl) isomers and their respective fluoro positional isomers in the pentyl group";

(*l*) by inserting, immediately after item (2DA) of paragraph 18, the following item:

"(2DB) 5-{3-[(1-Amino-3-methyl-1-oxobutan-2-yl) carbamoyl]-1H-indazole-1-yl}pentanoic acid and its N-(1-amino-1-oxopentan-2-yl) isomers";

(*m*) by inserting, immediately after item (2G) of paragraph 18, the following item:

"(2GA) N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide (also known as AB-FUBICA) and its N-(1-amino-1-oxopentan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring";

(*n*) by inserting, immediately after item (6F) of paragraph 18, the following item:

"(6G) [1-(5-Bromopent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as 5-Bromo-UR-144) and its bromo positional isomers in the pentyl group";

(*o*) by inserting, immediately after item (8AC) of paragraph 18, the following item:

"(8AD) [1-(5-Chloropent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as 5-Chloro-UR-144) and its chloro positional isomers in the pentyl group";

(*p*) by inserting, immediately after item (19AA) of paragraph 18, the following item: